Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Trial details
- Registry ID
- NCT01613118
- Phase
- Phase 2
The FDA approved Irbesartan (Avapro) on 30 Sep 1997.
Drug identity checked against registry records
Also recorded as Avapro; Irbesartan Tablets USP
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisNCT01613118 | TVTX | Phase 2 | Completed | 2016-06Actual |
| Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)NCT03493685 | TVTX | Phase 3 | Completed | 2023-03-20Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1997-09-30Day | Irbesartan | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020757", "applicant_as_listed_by_fda": "SANOFI AVENTIS US", "brand_names": ["AVAPRO"], "active_ingredients": ["IRBESARTAN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19970930", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |